<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03228797</url>
  </required_header>
  <id_info>
    <org_study_id>MRC-09/2014_07</org_study_id>
    <nct_id>NCT03228797</nct_id>
  </id_info>
  <brief_title>A Comparison of Postoperative Outcomes Provided by a Continuous Preperitoneal Infusion Versus Ultrasound Guided Rectus Sheath Block for Midline Emergency Laparotomy</brief_title>
  <official_title>A Comparison of Postoperative Outcomes Provided by a Continuous Preperitoneal Infusion Versus Ultrasound Guided Transversus Abdominis Plane Block for Abdominoplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dr Manar Mamdouh Fahmy Elsharkawi</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dubai Health Authority</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      aim of this study is to compare the postoperative analgesia provided bya continuous&#xD;
      preperitoneal infusion versus ultrasound guided rectus sheath block for midline emergency&#xD;
      laparotomy.&#xD;
&#xD;
      anticoagulated patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients and Methods:&#xD;
&#xD;
      This randomized prospective study will be carried out after the approval of Rashid Hospital's&#xD;
      Research Ethical Committee and patient's written informed consent.&#xD;
&#xD;
      Sixty adult patients , of both gender , 18-70 years old, ASA I-III who will be scheduled for&#xD;
      emergency laparotomy with upper abdominal midline incision will be included in the study.&#xD;
      Exclusion criteria will be patients with known allergic response or contraindications to&#xD;
      paracetamol, parecoxib, morphine or ropivacaine and pregnant women&#xD;
&#xD;
      The enrolled patients will be randomly assigned to one of three groups:&#xD;
&#xD;
      Group I ( 20 patients) will receive an ultrasound guided rectus sheath block by the end of&#xD;
      the surgery using 15 ml ropivacaine 0.5% on either side.&#xD;
&#xD;
      Group II ( 20 patients) for whom a 7.5 , 15 , 30 cm 19-gauge multiholed catheter will be&#xD;
      inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm&#xD;
      away from the lower end of the surgical incision through an introducer peel-away needle. The&#xD;
      length of the catheter will be established to guarantee homogenous distribution of the holes&#xD;
      all along the length of the incision of the fascia. The catheter will be allocated above the&#xD;
      peritoneum within the musculofascial layer and secured to the skin with an occlusive&#xD;
      transparent dressing. A 10 ml bolus of ropivacaine 0.2% will be administered through the&#xD;
      catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of&#xD;
      ropivacaine 10 ml/h.&#xD;
&#xD;
      Group III( 20 patients) a multiholed catheter will be inserted as in Group II and will&#xD;
      receive also an ultrasound guided rectus sheath block as described for Group I.&#xD;
&#xD;
      No premedication will be administered. General anesthesia will be induced using target&#xD;
      controlled intravenous infusion (TCI) using remifentanil (1-10 ng/ml effect concentration )&#xD;
      and propofol ( 1-10 mcg/ml effect concentration) titrated to Bi-spectral index (BIS) value&#xD;
      between 40-60.Once anesthesia level will be reached , succinyl choline 1mg/kg intravenously&#xD;
      will be given. After the airway will be secured , TCI will be adjusted to maintain BIS value&#xD;
      between 40 to 60.An initial dose of 0.1 mg/kg intravenous cisatracurium will be administered&#xD;
      and further doses will be given according to neuromuscular monitoring maintaining a train of&#xD;
      four (TOF) value of zero.&#xD;
&#xD;
      Pre-incision , all patients will receive 15 mg/kg intravenous bolus and 40 mg intravenous&#xD;
      parecoxib. 0.5 mg intravenous ketamine will be administered to avoid remifentanil's induced&#xD;
      hyperalgesia.&#xD;
&#xD;
      All patients will be mechanically ventilated to maintain normocapnia throughout the&#xD;
      procedure. Standard intraoperative monitoring will include electrocardiography, pulse&#xD;
      oximetry , automatic non-invasive blood pressure , end tidal capnography , Bi-spectral index&#xD;
      and train of four monitoring.&#xD;
&#xD;
      At the end of surgery and before extubation , patients who will be randomly assigned to Group&#xD;
      I will receive an ultrasound-guided bilateral rectus sheath block using 15 ml of ropivacaine&#xD;
      0.5% on each side.&#xD;
&#xD;
      For patients who will be assigned to either Group II or Group III , a 7.5 , 15 or 30 cm&#xD;
      19-gauge multiholed catheter will be inserted by the operating surgeon at the end of surgery&#xD;
      and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the&#xD;
      surgical incision through an introducer peel-away needle. The length of the catheter will be&#xD;
      established to guarantee homogenous distribution of the holes all along the length of the&#xD;
      incision of the fascia. The catheter will be allocated above the peritoneum within the&#xD;
      musculofascial layer and secured to the skin with an occlusive transparent dressing. A 10 ml&#xD;
      bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an&#xD;
      elastomeric pump delivering a continuous fixed -rate of ropivacaine 10 ml/h.&#xD;
&#xD;
      For patients who will be assigned to Group III will receive also an ultrasound-guided&#xD;
      bilateral rectus sheath block using 15 ml of ropivacaine 0.5% on each side.&#xD;
&#xD;
      Then the patients will be extubated and shifted to Post-Anesthesia Care Unit (PACU) where&#xD;
      they will be monitored for heart rate , blood pressure , oxygen saturation by pulse oximetry&#xD;
      and pain score using visual analogue scale (VAS) both at rest and deep breathing . These data&#xD;
      will be recorded every 15 minutes for the first hour.&#xD;
&#xD;
      After one hour , the patients will be discharged from PACU according to Modified Aldrete&#xD;
      Scoring if they will reach a score of 9 or more. All patients will receive parecoxib 40 mg&#xD;
      intravenously twice a day and paracetamol in a dose of 40 mg/kg intravenously in three&#xD;
      divided doses regularly for 48 hours postoperatively.&#xD;
&#xD;
      In the postoperative period, all the patients will be evaluated for their hemodynamic&#xD;
      variables ( heart rate , respiratory rate , arterial blood pressure and arterial oxygen&#xD;
      saturation ) and postoperative analgesia using VAS at rest and with deep breathing at&#xD;
      2,4,8,12,18,24,36 and 48 hours postoperatively.&#xD;
&#xD;
      If the patient's VAS will reach 4 at any time in the 48 hours postoperatively, 0.1 mg/kg&#xD;
      titrated intravenous morphine rescue analgesia will be administered and repeated if required&#xD;
      to maintain VAS less than 4.&#xD;
&#xD;
      All patients will respond to a quality of life questionnaire (QR 40) at 24 and 48 hours&#xD;
      postoperatively.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 11, 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>comparative study between 3 groups using ropivacaine</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>self reported pain intensity in the morning ,afternoon,evening, during activity over the past 2 days</measure>
    <time_frame>2 days</time_frame>
    <description>each item is scored (0-10)0=no pain&amp; 10= the worst</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Abdominal Pain</condition>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>( 20 patients) will receive an ultrasound guided rectus sheath block by the end of the surgery using 15 ml ropivacaine 0.5% on either side.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>( 20 patients) multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer, a10 ml bolus of ropivacaine 0.2% will be administered through the catheter and then connected to an elastomeric pump delivering a continuous fixed -rate of ropivacaine 5ml/h.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>( 20 patients) a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>an ultrasound guided rectus sheath block</intervention_name>
    <arm_group_label>Group I</arm_group_label>
    <other_name>naropine 0.5%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>multiholed catheter</intervention_name>
    <description>gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision</description>
    <arm_group_label>Group II</arm_group_label>
    <other_name>naropine 0.2%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>an ultrasound guided rectus sheath block &amp;multiholed catheter</intervention_name>
    <description>a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.</description>
    <arm_group_label>Group III</arm_group_label>
    <other_name>naropine 0.5% &amp; naropine/ropivacaine 0.2%</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ASA-1 to ASA-3,emergency midline laparotomy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  ASA-4 &amp; above,allergic patients to the study's medications ,morbid obeses&#xD;
             patients,patient refusal,age below 18yrs&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>DR.HANY GREISS, consultant</last_name>
    <role>Principal Investigator</role>
    <affiliation>DHA -Rashid hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DR.MANAR MAMADOUH, specialist</last_name>
    <role>Principal Investigator</role>
    <affiliation>DHA -Rashid hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DR.MANSOUR NADHRI, consultant</last_name>
    <role>Study Director</role>
    <affiliation>DHA -Rashid hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>DR.OSAMA ALANI, senior specialist</last_name>
    <role>Study Director</role>
    <affiliation>DHA -Rashid hospital</affiliation>
  </overall_official>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>July 6, 2017</study_first_submitted>
  <study_first_submitted_qc>July 24, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">July 25, 2017</study_first_posted>
  <last_update_submitted>August 24, 2017</last_update_submitted>
  <last_update_submitted_qc>August 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Dubai Health Authority</investigator_affiliation>
    <investigator_full_name>Dr Manar Mamdouh Fahmy Elsharkawi</investigator_full_name>
    <investigator_title>anaesthesiologist</investigator_title>
  </responsible_party>
  <keyword>pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Abdominal Pain</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ropivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 11, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT03228797/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

